Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is currently conducting a Phase 3 clinical study titled ‘A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration.’ The study aims to evaluate the progression rate of Geographic Atrophy in patients treated with cemdisiran alone or in combination with pozelimab compared to a placebo, with a focus on safety, drug levels in the blood, and potential antibody development.
The interventions being tested are two experimental drugs, pozelimab and cemdisiran, administered via subcutaneous injection. Pozelimab is tested in combination with cemdisiran, while cemdisiran is also tested as a monotherapy. The study seeks to determine their effectiveness in slowing the progression of Geographic Atrophy, a late-stage condition of Age-related Macular Degeneration affecting central vision.
This interventional study is designed with a randomized, parallel assignment model and employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused, aiming to provide insights into the efficacy and safety of the drug interventions.
The study began on August 2, 2024, with the latest update submitted on August 26, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected and analyzed.
From a market perspective, the successful development of treatments for Geographic Atrophy could significantly impact Regeneron’s stock performance and investor sentiment, given the high prevalence of Age-related Macular Degeneration. This study positions Regeneron in a competitive landscape where advancements in AMD treatments are highly sought after.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.